Trump makes new free trade agreement with China before Jan 20, 2029

Step-by-step analysis grounded in April 1, 2026:

1. Critical Resolution Criteria Understanding: The bet requires a "new free trade agreement with China" that has "become law" before January 20, 2029. This is NOT asking about:

• Executive agreements or frameworks
• Temporary truces or tariff pauses
• Memorandums of understanding

A formal FTA requires Congressional ratification under Trade Promotion Authority or through separate Congressional approval legislation.

2. Current Situation Assessment:

Positive signals:

• Trump is CURRENTLY in Beijing (March 31-April 2, 2026) for an official state visit, indicating active diplomatic engagement
• Economic pressures building: unemployment at 4.4% with job losses (-92k), which could motivate deal-making
• Previous 2025 trade framework shows willingness to negotiate, though it fell short of FTA status
• 2 years, 9.5 months remain until resolution deadline

Negative structural barriers:

• Supreme Court ruling (Feb 20, 2026): Struck down Trump's IEEPA tariffs 6-3, forcing reliance on Congressional authority for trade policy
• Congressional opposition: BIOSECURE Act passage in 2026 NDAA demonstrates strong bipartisan anti-China sentiment on national security
• Historical precedent: The U.S. has NEVER ratified a comprehensive FTA with China. Base rate <5%
• Legal complexity: Full FTA ratification process typically takes 2-4 years even under favorable conditions
• 2025 framework clarification: Legal experts emphasized the Oct/Nov 2025 agreement was a temporary truce, NOT an FTA

3. Political and Economic Context:

The Fed's hawkish stance (3.50%-3.75% rates, core PCE at 2.7%, only one cut expected in 2026) reflects economic uncertainty partly driven by trade tensions. The Supreme Court ruling fundamentally altered Trump's trade policy toolkit - he can no longer unilaterally impose sweeping tariffs and must work through Congress or temporary statutory authorities (like the 150-day Section 122 tariff expiring July 2026).

4. Probability Pathways:

For this to resolve YES, the following must occur:

1. Trump and Xi negotiate comprehensive FTA during current visit or subsequent talks (20% probability given current engagement)
2. Agreement satisfies both nations' core demands on tariffs, technology, IP, agricultural access, etc. (30% conditional probability - extremely difficult given current tensions)
3. Agreement passes Congressional approval with bipartisan support despite BIOSECURE Act mentality (25% conditional probability - major barrier)
4. All this occurs within 33 months (timeline is tight but feasible if negotiations accelerate)

Combined pathway probability: 0.20 × 0.30 × 0.25 = 0.015 (1.5%)

However, accounting for:

• Potential economic deterioration forcing action (labor market weakening)
• Trump's deal-making focus and current diplomatic engagement
• Possibility of limited-scope FTA rather than comprehensive agreement
• Alternative fast-track scenarios

Adjusted estimate: 18%

5. Market Comparison:

Market odds: 35.5% My estimate: 18%

The market appears to be:

• Overweighting the significance of the current Beijing state visit
• Possibly conflating executive agreements (like 2025 framework) with legally binding FTAs
• Underestimating Congressional opposition barriers post-BIOSECURE Act
• Not fully accounting for the Supreme Court ruling's constraint on executive trade authority

Edge Assessment: The market is pricing this roughly 2x higher than warranted. There may be value in the NO position, though the ongoing Beijing visit creates short-term uncertainty that could move prices.

MODERATE EDGE TOWARD NO: Market probability of 35.5% appears approximately 2x higher than justified. Key reasons for discrepancy:

1. Legal misunderstanding: Market may be conflating executive trade agreements (which are likely) with formal FTAs requiring Congressional ratification (which are unlikely). The 2025 framework was NOT an FTA but some market participants may have counted it as precedent.

2. Recency bias: Trump's current Beijing state visit (happening RIGHT NOW as of April 1, 2026) is likely inflating short-term optimism. The visit signals engagement but not necessarily FTA capability.

3. Underestimating Supreme Court constraint: The February 2026 ruling fundamentally changed Trump's trade authority. Market hasn't fully priced the shift from unilateral executive power to Congressional dependency.

4. Congressional barrier: BIOSECURE Act passage shows strong anti-China consensus. Market pricing doesn't reflect ~75% probability of Congressional blocking even if agreement is negotiated.

5. Base rate neglect: Zero historical precedent for U.S.-China FTA. Market should anchor closer to 5-10% base rate rather than 35.5%.

Suggested position: NO at current 64.5% odds offers value, though wait 48-72 hours for Beijing visit outcomes before entering. If visit produces concrete FTA negotiation announcement, probability could legitimately increase to 25-30%. If visit produces only vague framework, probability should decline to 12-15%.

Risk caveat: The 72% confidence level reflects genuine uncertainty about resolution criteria interpretation and potential for surprising diplomatic breakthrough during ongoing state visit."